Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

SS) PER COMMON SHARE Basic $ 0.01 $ (0.15) $ 0.32 $ (1.11) ============================================ Diluted $ 0.01 $ (0.15) $ 0.31 $ (1.11) ============================================ SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE Basic 47,932,029 45,222,053 47,880,737 44,348,537 ============================================ Diluted 49,028,254 45,222,053 48,326,718 44,348,537 ============================================ Balance Sheet Information: September 30, 2009 December 31, 2008* ------------------ ------------------ (unaudited) Cash, cash equivalents, interest Receivable and short-term investment securities $33,687 $15,467 Long-term investment securities 7,333 7,185 Total assets 45,458 26,634 Accumulated deficit (316,775) (331,918) Stockholders' equity (deficiency) 34,959 (1,489) * Condensed from audited financial statements.

SOURCE Keryx Biopharmaceuticals, Inc.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 The ... that Drive Medical Design and Manufacturing has joined the ... its CEO Harvey Diamond have been actively ... year history, as it has quickly grown into a ... corporate partners like Drive allows AAHomecare to increase efforts ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... 2011 BioMed Realty Trust, Inc. (NYSE: ... of its 2010 distributions as follows:Security Description: Common ... ShareAllocable to 2010Taxable Ordinary DividendReturn of CapitalLong-Term Capital ... , $0.140000 , $0.090527 , $0.049473 , $0.000000 ...
... Jan. 19, 2011 Pervasis Therapeutics, Inc. today announced ... therapy (PVS-30200) to target and regulate cell stroma (the ... supporting cell types distinct from cancer cells) in order ... advancing solid tumor growth and metastasis (the spread of ...
Cached Medicine Technology:BioMed Realty Trust Announces Tax Treatment of 2010 Distributions 2Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 2Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 3Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 4Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 5
(Date:9/20/2014)... Lifeinsurancequoteterm.net has released a new blog post ... insurance plan provides for vulnerable family members. , ... a top priority for every provider. It is now ... examinations and visiting a doctor. , Life insurance ... coverage up to $300,000, but only to healthy applicants. ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, “Symbicort ... The asthma market saw very slow growth over ... with relatively efficacious standard therapies, such as short-acting ... long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has ... launch of seven novel targeted biologic agents and ...
(Date:9/20/2014)... have advised their patients against drinking coffee and wine. Dr. ... advice and changing his stance after considering two recent studies ... health. “There’s good news and great news,” says Dr. Wells, ... against gum disease, and red wine can help fight cavities!” ... September 2014 issue of Boston University School of Medicine ...
(Date:9/20/2014)... QueenBeeTickets.com is ready to offer discount Ariana ... will visit many cities in North America next year ... April. , Click Here to view the ... , The star’s fans are not going to want ... singer in a live performance. Ariana Grande concert tickets ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge ... latest article , “We know that you want to care ... we want to do as well.” , The article explains ... from their Family Physicians who practice obstetrics while pregnant, during ... , To learn more about Community Health Center of Snohomish ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2
... Beginning, March 17, 2009, the first of two effective ... Final Rule goes into effect. This final rule ... Version 4010A1 and National Council for Prescription Drug Programs ... transactions. Compliance with these standards is mandatory by ...
... Quantum Group, Inc. (NYSE Amex: QGP ) ( ... received notice on March 17, 2009 from the NYSE Amex ... it is not in compliance with Section 1003(a)(iv) of the ... sustained losses which are so substantial in relation to its ...
... may be driving the trend, doctors say , , FRIDAY, March ... reporting a sharp increase in the number of vasectomies performed ... many of his clients are from the beleaguered financial industry. ... both to a decreased desire to have children because of ...
... rigorous environmental cleaning intervention can reduce the transmission of ... organisms in hospital intensive care units (ICUs), according to ... of the Society for Healthcare Epidemiology of America (SHEA). ... reduced the spread of MRSA to patients exposed to ...
... for decades as a significant problem affecting astronauts. ... gravity is causing astronauts on the International Space Station ... in key regions of the body each month than ... time back here on Earth., Now, by simulating spaceflight ...
... implications for public safety, experts say , , FRIDAY, ... percent of candidates for fire and ambulance services ... situation that has major consequences for public health ... and musculoskeletal injury are important causes of [disability ...
Cached Medicine News:Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 2Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 3Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 2Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 3Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 4Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 5Health News:With the Economy Down, Vasectomy Rates Are Up 2Health News:Environmental Cleaning Intervention Reduces Transmission of Multidrug-Resistant Organisms in ICUs 2Health News:University of Washington scientists one step closer to stopping bone loss during spaceflight 2Health News:Most New EMS Recruits Overweight or Obese 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: